|
|
Odalasvir市场分析报告
|
Hepatitis C: KOL Insight As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus has shifted to cure, and physicians now have more ...
Hepatitis C [2016]: Bulletin #3 ... triple combination JNJ-4178 (simeprevir/odalasvir/AL-335) in an ongoing Phase II study; AbbVie ...
|
|
|
|